Literature DB >> 33104403

Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism".

Nicholas A Marston1, Christian T Ruff1, Marc S Sabatine1.   

Abstract

Entities:  

Year:  2020        PMID： 33104403      PMCID： PMC7641032          DOI： 10.1161/CIRCULATIONAHA.120.050174

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  2 in total

1.  The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.

Authors:  Christian T Ruff; Marc S Sabatine; Nicholas A Marston; Yared Gurmu; Giorgio E M Melloni; Marc Bonaca; Baris Gencer; Peter S Sever; Terje R Pedersen; Anthony C Keech; Carolina Roselli; Steven A Lubitz; Patrick T Ellinor; Michelle L O'Donoghue; Robert P Giugliano
Journal:  Circulation       Date:  2020-03-29       Impact factor: 29.690

2.  Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.

Authors:  Gregory G Schwartz; Philippe Gabriel Steg; Michael Szarek; Vera A Bittner; Rafael Diaz; Shaun G Goodman; Yong-Un Kim; J Wouter Jukema; Robert Pordy; Matthew T Roe; Harvey D White; Deepak L Bhatt
Journal:  Circulation       Date:  2020-03-29       Impact factor: 29.690
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.